At the regular policy briefing of the People's Government of Shandong Province on September 21, Luo Xinjun, a first-level inspector of the Department of Industry and Information Technology of Shandong Province, introduced that Shandong,  a major pharmaceutical province, has thoroughly implemented the "chain leader system" of the pharmaceutical industry chain, and centered on extending, supplementing and strengthening the chain, contributing to promoting the integrated and coordinated development of the pharmaceutical industry. The scale of the pharmaceutical industry has consistently ranked among the top in China for many years, accompanied by positive results in high-quality development. Currently, Shandong's pharmaceutical industry represents a significant portion, constituting one-tenth of the national scale. In 2022, 132 new pharmaceutical products obtained approval, 12 enterprises were listed among the Top 100 Pharmaceutical Enterprises in China's Pharmaceutical Industry, and 2 enterprises made it into the 2022 Medtech Big 100.

Going forward, Shandong will prioritize global cutting-edge pharmaceutical and medical technologies and the health demands of the people. Shandong will place emphasis on the overall layout of the whole pharmaceutical industry, continuously improve the innovation system, enhance the industrial innovation ecosystem, and vigorously promote collaborative innovation and development in the pharmaceutical industry. Shandong will cultivate and build advanced biomedical industrial bases and high-end medical device industrial clusters.